Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4231 - Cabazitaxel plus prednisone and prophylaxis of neutropenia complications in the treatment of metastatic castration-resistant prostate cancer after failure to docetaxel: a multicenter, non-comparative, open-label, phase IV study

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Supportive Care and Symptom Management;  Prostate Cancer

Presenters

Fernando Maluf

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

F.C. Maluf1, D. Cubero2, F.A.M. de Oliveira3, P.E.R. Liedke4, L. Brust5, C.G. Inocêncio6, F.S.M. Monteiro7

Author affiliations

  • 1 Clinical Oncology Department, Hospital Beneficencia Portuguesa of Sao Paulo, 04002-030 - Sao Paulo/BR
  • 2 Hematology And Oncology, Faculty of Medicine of ABC, 09060-650 - Santo André/BR
  • 3 Clinical Oncology Department, Hospital Erasto Gaertner, 81520-060 - Curitiba/BR
  • 4 Oncology Clinical Search Unit, Hospital de Clínicas de Porto Alegre, 90035-903 - Porto Alegre/BR
  • 5 Oncology Department, Hospital Bruno Born, 95900-000 - Lageado/BR
  • 6 Oncology And Hematology, “Dr. Ademar Lopes” Search Center, Cuiaba/BR
  • 7 Clinical Oncology, Hospital Santa Lucia, Brasilia/BR
More

Resources

Abstract 4231

Background

This study aimed to evaluate the effectiveness of granulocyte colony-stimulating factor (G-CSF) and ciprofloxacin in the prophylaxis of hematological complications in mCRPC patients treated with cabazitaxel after docetaxel failure and at risk for neutropenia.

Methods

Phase IV, non-randomized, open-label, single-arm interventional study, with men aged ≥65 years (or 12 weeks, that provided informed consent. Cabazitaxel 25 mg/m2 was given with prednisone on day1 every 21 days. G-CSF was administered on days 2 to 8 of each cycle or until ANC >2,000/mm3 and ciprofloxacin 1000mg on days 5 to 12. Primary endpoint was the rate of neutropenia grade ≥3 during the first cycle; secondary endpoints were the rate of neutropenia grade ≥3, febrile neutropenia, diarrhea grade ≥3, PSA response and quality of life (FACT-P) during treatment. Statistical significance was set at 0.05 and 95% confidence intervals were determined.

Results

46 patients with median age 71.5 years (mean: 71.8 years) and 69.0 months on median since diagnosis (mean: 75.2 months) of prostatic cancer were included. Among the 45 treated patients, exposed to a median of 9.0 cycles (mean: 9.5 cycles) during 210 days, 40.0% (95% CI, 25.7%-54.3%) presented one episode of neutropenia grade ≥3 during the first cycle. During treatment, 42.2% patients presented at least one neutropenia grade ≥3; febrile neutropenia occurred in one patient (2.2%) as well as diarrhea grade ≥3. Twenty-nine patients (64.4%) achieved PSA response and 77.2% improved FACT-P score in at least one visit. Three patients (6.7%) had a serious TEAEs leading to death (none related to treatment), and 13.3% had 7 TEAEs leading to treatment discontinuation (3 related to treatment).

Conclusions

Prophylactic G-CSF and ciprofloxacin was effective in the prevention of neutropenia grade ≥3 and other hematological complications during the mCRPC treatment with cabazitaxel 25 mg/m2 in patients who were at risk for neutropenia.

Clinical trial identification

NCT01649635 - Global Statitic Report: January 26th 2017.

Legal entity responsible for the study

Sanofi

Funding

Sanofi

Disclosure

F.C. Maluf: Speaker at Sanofi-Aventis, Janssen, Bayer, AstraZeneca, Astellas, Ferring, Ache. Clinical trial investigator at Sanofi-Aventis, GSK, Janssen, Astellas, Bayer. Member of advisory board at Sanofi-Aventis, Janssen, Bayer, Astellas. F.A.M. de Oliveira: Speaker at Janssen. P.E.R. Liedke: Grants from Roche, Pfizer, Sanofi. L. Brust: Advisory Board Boheringer, Janssen, Agendia. F.S.M. Monteiro: Speaker at Sanofi, BMS, Pfizer, Janssen, Astellas e Merck Serono. Advisory Board at Janssen. Chair LACOG GU (Latin America Cooperative Oncology Group - Genito–Urinary Tumors). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.